ClinicalTrials.gg
Not yet recruitingNCT07862816Updated Oct 7, 2026

Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign

An observational study in Lung Cancer (Diagnosis), sponsored by Intuitive Surgical. Not yet recruiting at 4 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Intuitive Surgical · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
151
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Lung Neoplasms by Intuitive Surgical — 4 open to participants now, 7 under way, none of them phase 3. Lung Neoplasms · Intuitive Surgical.

Started
2027
the only one that year
Observational
9 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Lung Neoplasms by Intuitive Surgical, this one is the only one that started in 2027, is one of 9 observational ones, and was the 14th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

4 of the 14 studies in Lung Neoplasms by Intuitive Surgical are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lung Neoplasms by Intuitive Surgical, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the diagnostic performance and safety of robotic-assisted bronchoscopy using the Ion Endoluminal System in adults with small lung nodules that do not show a bronchus sign on CT imaging.

The main questions it aims to answer are:

  • How effective is robotic-assisted bronchoscopy in obtaining a diagnosis for small lung nodules without a bronchus sign?
  • How safe is the procedure, including the risk of complications such as pneumothorax and bleeding?

Participants who are already scheduled to undergo lung nodule biopsy using the Ion Endoluminal System and integrated mobile cone-beam CT (mCBCT) as part of their routine clinical care will be enrolled in this study.

Read the detailed description

Lung cancer remains a leading cause of cancer-related mortality worldwide, and delayed diagnosis is an important contributor to poor clinical outcomes. Earlier and more accurate diagnosis of small peripheral pulmonary nodules may facilitate timely clinical decision-making and treatment.

The Ion Endoluminal System is a robotic-assisted bronchoscopy platform designed to provide access to peripheral pulmonary lesions. When integrated with mobile cone-beam computed tomography (mCBCT), the system may provide additional imaging information to support localization of small pulmonary nodules during bronchoscopic biopsy. However, prospective clinical data on the diagnostic performance of this integrated approach in small, bronchus sign-negative pulmonary nodules remain limited.

ROBISN is a prospective, multicenter, observational study designed to evaluate the clinical performance of bronchoscopic biopsy using the integrated Ion Endoluminal System and mCBCT platform in patients with small peripheral pulmonary nodules that are considered challenging for conventional bronchoscopic biopsy.

The study will enroll adult patients who are already clinically planned to undergo bronchoscopic biopsy using the Ion Endoluminal System and mCBCT as part of their routine clinical care. Eligible patients will have a single target pulmonary nodule with a maximum diameter of 20 mm or less, measured on axial, sagittal, and coronal computed tomography images. The target nodule must also be bronchus sign-negative on thin-section computed tomography.

This is an observational study, and participation in the study will not determine the patient's clinical diagnostic or treatment pathway. All bronchoscopic procedures, imaging, biopsy techniques, pathology assessments, subsequent diagnostic evaluations, and treatment decisions will be performed according to the participating institution's standard clinical practice and the treating physician's judgment.

The study will prospectively collect information related to patient and target lesion characteristics, procedural details, use of adjunctive imaging and biopsy modalities, biopsy results, pathology findings, procedure-related adverse events, and subsequent clinical information used to establish the final diagnosis of the target pulmonary nodule.

Diagnostic outcomes will be assessed using information obtained from the index bronchoscopic biopsy together with subsequent pathology, imaging, clinical follow-up, or other diagnostic procedures, as applicable. Follow-up information will be collected prospectively to evaluate the diagnostic outcome of cases in which the initial biopsy result is not immediately definitive and to characterize the clinical course of the target lesion over time.

Safety outcomes will include clinically relevant procedure-related adverse events, including events such as pneumothorax and bleeding. Other procedural and clinical variables will also be collected to characterize the performance of the integrated Ion Endoluminal System and mCBCT approach in this patient population.

The results of this study are intended to provide prospective, multicenter evidence regarding the use of robotic-assisted bronchoscopy combined with mCBCT for the biopsy of small, bronchus sign-negative pulmonary nodules and to better characterize its diagnostic performance and safety in routine clinical practice.

03

Conditions studied

  • Lung Cancer (Diagnosis)
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults planned to undergo a pulmonary nodule biopsy using the Ion Endoluminal System and integrated mobile cone beam CT (mCBCT)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is aged 19 years or older at the time of consent.
  • Single pulmonary nodule planned for with the integrated Ion Endoluminal System/mCBCT platform.
  • Target pulmonary nodule (solid or subsolid) with overall largest diameter ≤20 mm and solid component >5 mm in largest diameter, measured across axial, sagittal, and coronal CT.
  • Target pulmonary nodule is bronchus sign negative on thin section CT (≤1 mm).

Exclusion criteria

Exclusion Criteria:

  • Patient is planned for non-surgical oncological treatment (e.g., SBRT, chemotherapy) regardless of outcome.
  • Patient with a nodule that is amenable to linear EBUS sampling.
  • More than one target pulmonary nodule planned for biopsy during the index bronchoscopy procedure.
  • Patient has a history of pneumonectomy.
  • Patient is legally incapacitated or in a legal/court-ordered institution or is part of a known vulnerable population, including but not limited to dependency on the Sponsor, Institution, or Investigator.
  • Patient is not willing or able (as deemed by the Investigator) to comply with study participation requirements.
  • Investigator, in their professional opinion, has decided that it is in the patient's best interest not to participate in the clinical study.
  • Patient is pregnant, nursing, or planning to become pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
151 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Patients Undergoing Ion Robotic Bronchoscopy With mCBCT

    Adult patients with a single small, bronchus sign-negative pulmonary nodule who are clinically planned to undergo bronchoscopic biopsy using the integrated Ion Endoluminal System and mobile cone-beam computed tomography (mCBCT) platform as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Diagnostic yield assessed using the ATS/ACCP consensus definition.

    Diagnostic yield will be calculated according to the ATS/ACCP consensus definition using the diagnosis established from the index biopsy procedure.

    Time frame: At completion of index biopsy procedure

Secondary outcomes

  1. Intermediate diagnostic yield

    Time frame: Through establishment of final diagnosis (up to 12 months)

  2. Sensitivity for malignancy

    Time frame: Through establishment of final diagnosis (up to 12 months)

  3. Rate of pneumothorax (with and without intervention or hospitalization)

    Time frame: within 7 days post procedure.

  4. Rate of intra-procedure airway bleeding graded using the Nashville Bleeding Scale

    Time frame: Procedure day

  5. Procedure time (ssRAB catheter in or out)

    Time frame: During the index biopsy procedure.

  6. Total radiation dose

    Time frame: During the index biopsy procedure.

  7. Number of cone beam CT (CBCT) spins

    Time frame: During the index biopsy procedure

Other outcomes

  1. Rate of successful tool in lesion (TIL)

    Time frame: During the index biopsy procedure.

  2. rEBUS view at time of tissue sampling (when radial EBUS is used)

    Time frame: During the index biopsy procedure.

  3. Rate of procedure related adverse events.

    Time frame: 30 days post-procedure or until the next invasive diagnostic or therapeutic intervention, whichever occurs first.

  4. Time from identification of nodule to diagnosis

    Time frame: Through establishment of final diagnosis (up to 12 months).

  5. Rate and type of imaging and/or diagnostic interventions performed from nodule identification to procedure

    Time frame: Up to the index biopsy procedure.

  6. Percentage of patients and timepoint for invasive mediastinal staging.

    Time frame: Through establishment of final diagnosis (up to 12 months).

  7. Adequacy of biopsy sample for molecular/immunohistochemistry (IHC) testing when indicated.

    Time frame: Up to 30 days after the index biopsy procedure.

  8. Patient-reported outcomes measured with the EQ-5D-5L.

    Time frame: Up to 7 days post-procedure.

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Nov 2028, 22 months later.

Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 22 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Jan 2027
Primary completionEst.
Nov 2028
CompletionEst.
Mar 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862816
Lead sponsor
Intuitive Surgical
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jan 2027 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Changmin Oh
Contact
changmin.oh@intusurg.com
+82-2-3271-3200 ext. 3253
Chunsik Eum
Contact
chunsik.eum@intusurg.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion